Effects of biological response modifiers in psoriasis and psoriatic arthritis
Goedkoop, A.Y.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Early effects of tumour necrosis factor α blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.

Goedkoop AY, Kraan MC, Teunissen MBM, Picavet DI, de Rie MA, Bos JD, Tak PP

Ann Rheum Dis 2004; 63: 769-773
Abstract

Background: Tumour necrosis factor α (TNFα) blockade using infliximab, a chimeric anti-TNF-α antibody, is an effective treatment for both psoriasis and psoriatic arthritis (PsA).

Objective: To analyze the early effects of infliximab treatment on serial skin and synovial tissue biopsy samples.

Methods: Twelve patients with both active psoriasis and PsA received a single infusion of either infliximab (3mg/kg) (n=6) or placebo (n=6) intravenously. Synovial tissue biopsies and lesional skin biopsy specimens were obtained at baseline and 48 hours after treatment. Immunohistochemical analysis was performed to analyze the inflammatory infiltrate. In situ detection of apoptotic cells was performed by TUNEL assay and by immunohistochemical staining with anti-caspase-3 antibodies. Stained tissue sections were evaluated by digital image analysis.

Results: A significant reduction in mean (SEM) T-cell numbers was found in both lesional epidermis (baseline 37 (11) cells/mm, 48 hours 26 (11), p = 0.028) and synovial tissue (67 (56) cells/mm² v 32 (30), p = 0.043) after infliximab treatment, but not after placebo treatment (epidermis 18 (8) v 43 (20), NS; synovium 110 (62) v 46 (21), NS). Similarly, the number of macrophages in the synovial sublining was significantly reduced after anti-TNFα treatment (100 (73) v 10 (8), p = 0.043). The changes in cell numbers could not be explained by induction of apoptosis at the site of inflammation.

Conclusion: The effects of anti-TNFα therapy in psoriasis and psoriatic arthritis may be explained by decreased cell infiltration in lesional skin and inflamed synovial tissue early after initiation of treatment.
Introduction

Tumor necrosis factor α (TNFα) is a pivotal cytokine in various chronic inflammatory disorders, including rheumatoid arthritis (RA) and Crohn’s disease. The central role of this cytokine has been emphasized by the therapeutic efficacy of infliximab, a chimeric TNFα neutralizing antibody (1-3). Psoriasis is a common dermatological disorder, affecting approximately 1.5% of the population, and is characterized by epidermal hyperproliferation, increased dermal angiogenesis and infiltration of mononuclear cells in dermis and epidermis. Psoriatic arthritis (PsA) affects 5-40% of the patients with psoriasis, and is diagnosed by clinical signs and symptoms, such as absence of rheumatoid factor, and a presentation of symmetric, oligoarticular, axial and/or distal interphalangeal joint involvement (4). Like RA, PsA can cause considerable joint damage, disability, and impairment of quality of life in a significant proportion of patients, with the additional handicap of skin involvement. The synovium of patients with PsA has not been studied as extensively as that of patients with RA. Recent studies suggest that the histology shows both differences and similarities between the two inflammatory joint diseases (5,6). The cell infiltrate in both joint diseases is composed predominantly of CD3+ T lymphocytes, located around the small blood vessels and near the hyperplastic intimal lining layer. Other cell types found in the synovial tissue of patients with PsA include macrophages and some neutrophils, located near the intimal lining layer and around the blood vessels (7).

Although the cause of psoriasis and PsA is still unknown, increasing evidence shows that the inflammatory response is primarily initiated by activated T cells in the epidermis and dermis of psoriatic lesions and in the synovium of affected joints (8-11). Proinflammatory cytokines, such as TNFα, have a key role in the inflammatory cascade in psoriasis and PsA as illustrated by the increased TNFα expression in psoriatic skin lesions (12, 13) and inflamed synovial tissue (14, 15). Consisted with this notion, infliximab has been reported to be clinically effective for both psoriasis and PsA (16-20), but the mechanism of action is not precisely known. To provide more insight into the effects of infliximab treatment in psoriasis and PsA, we performed a single centre, randomized, placebo controlled study to investigate the early changes at the site of inflammation.
Patients and methods

Patients Twelve patients with both active skin disease and active joint inflammation, diagnosed with PsA at least 12 months before inclusion, were evaluated in this prospective, single centre, double blind, randomized, placebo controlled study. Active arthritis was defined as at least three tender joints (28 joint count and both ankles (21)), and physician’s and patient’s joint assessment as moderate or worse, despite concurrent methotrexate (MTX) treatment at maximal tolerable dose (5-20 mg/week). Active psoriasis was defined as at least two psoriatic plaques. The dosage of MTX was kept stable at least 28 days before inclusion in the study. Stable doses of non-steroidal anti-inflammatory drugs were allowed, but prednisolone therapy was not. Only patients with a swollen knee or wrist joint were included. After randomization patients received a single infusion of infliximab 3 mg/kg or placebo.

All patients gave informed consent before inclusion, and the study protocol was reviewed and approved by medical ethics committee of the Academic Medical Center/University of Amsterdam. The study was conducted according to the Declaration of Helsinki principles.

Synovial biopsies At baseline and 48 hours after infusion of either infliximab or placebo, small bore arthroscopy was performed under local anesthesia of the same knee (n= 8) or wrist (n= 4) joint. An average of at least 12 synovial tissue samples was obtained from the entire joint using a 2.5 mm grasping forceps (Storz, Tuttlingen, Germany) on each occasion, as described previously (22). Six samples were fixed in formaldehyde and embedded in paraffin, 6 samples were snap-frozen en bloc in Tissue Tek OCT (Miles, Elkhart, IN), and stored in liquid nitrogen until sectioning. Sections (5 μm) were cut in a cryostat and mounted on glass slides (Star Frost adhesive slides, Knittelgläser, Germany), which were stored at -70°C until immunohistochemical analysis could be performed.

Skin biopsies At baseline and 48 hours after infusion with either infliximab or placebo, 4 mm punch biopsies were taken from the inside border of a target psoriatic plaque, preferentially from an area not exposed to sun. Biopsy samples from each individual patient were obtained from the same target lesion, separated by at least 1 cm. The biopsies were randomly coded, snap-
frozen in Tissue Tek OCT (Sakura Finetek Europe, Zoeterwoude, The Netherlands), and stored at -70°C until further processing. Cryostat sections (5 μm) were cut and mounted on glass slides (Star Frost adhesive slides), and stored at -70°C until immunohistochemical staining.

**Immunohistochemistry** The synovium and skin sections were stained with the monoclonal antibodies anti-CD3 (Becton Dickinson, San Jose, CA) to detect T lymphocytes, and anti-caspase-3 (Phar mingen, Becton Dickinson (skin), Cell Signaling Technology, Leusden, The Netherlands (synovium)) to detect apoptotic cells. In addition, the synovial tissue was stained with anti-CD68 (clone EBM11, Dako, Glostrup, Denmark) to detect macrophages. The staining procedure was performed as described previously (23). After a primary incubation step with monoclonal antibodies, bound antibody was detected according to a three step immunoperoxidase method. Horseradish peroxidase activity was detected using a hydrogen peroxide as substrate and aminoethylcarbazole as dye, producing a reddish color.

**TUNEL assay** A TUNEL assay was performed according to the manufacturer’s instructions (Roche, Mannheim, Germany). In short, apoptotic cells in frozen synovial tissue en skin tissue were detected by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling of apoptosis induced DNA strand breaks, using in situ cell death detection assay.

**Digital image analysis** All sections were randomly coded and analyzed by computer assisted image analysis, as previously described in detail (24). For the synovial tissue samples, three separate regions of six high power fields (2.1 mm²) were evaluated. Macrophage (CD68) expression was analyzed separately in the intimal lining layer and the synovial sublining. Caspase-3 expression was measured as integrated optical density, a product of staining area and intensity.

For the skin tissue samples, one single region of 20 high power fields (2.1 mm²) including both epidermis and dermis was analyzed. The images were acquired and analyzed using Syndia algorithm on a Qwin based analysis system (Leica, Cambridge, UK), as described previously.
Statistical analysis SPSS 10.1.4 for Windows (SPSS, Chigaco, IL) was used for statistical analysis. The Wilcoxon signed rank test for matched pairs was used to compare data within each group. Results were expressed as mean (SEM).

Results

Patient characteristics Six men and six women were included in the study, and randomly allocated to receive either infliximab or placebo. Clinical baseline characteristics in both groups were comparable (table 1). From one of the patients, skin biopsy samples were not obtained for technical reasons. From another patient included in the study, the synovial tissue biopsy at baseline was not eligible for immunohistochemical analysis for quality reasons and, therefore, all samples from this patient were excluded from analysis.

Table 1. Baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Infliximab (n=6)</th>
<th>Placebo (n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>53 (35-70)</td>
<td>45 (26-60)</td>
</tr>
<tr>
<td>Male: female</td>
<td>3:3</td>
<td>3:3</td>
</tr>
<tr>
<td>Duration of joint disease (years)</td>
<td>9 (5-13) *</td>
<td>9 (1-22)</td>
</tr>
<tr>
<td>Duration of skin disease (years)</td>
<td>24 (10-41)</td>
<td>17 (2-38) *</td>
</tr>
<tr>
<td>DAS</td>
<td>6.8 (5.0-7.9) *</td>
<td>5.7 (4.8-8.2)</td>
</tr>
<tr>
<td>30 Tender joint count</td>
<td>19 (2-26) *</td>
<td>9 (2-25)</td>
</tr>
<tr>
<td>30 Swollen joint count</td>
<td>15 (9-21) *</td>
<td>7 (2-26)</td>
</tr>
<tr>
<td>VAS</td>
<td>61 (65-90) *</td>
<td>68 (36-93)</td>
</tr>
<tr>
<td>CRP</td>
<td>23 (10-36) *</td>
<td>28 (7-65)</td>
</tr>
<tr>
<td>PASI</td>
<td>13.7 (1-29.8)</td>
<td></td>
</tr>
<tr>
<td>10.5 (5-19.0) *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX dosage (mg/week)</td>
<td>10 (5-20)</td>
<td>10 (5-20)</td>
</tr>
</tbody>
</table>

* n=5. DAS, Disease Activity Score; VAS, visual analogue scale; CRP, C reactive protein; PASI, Psoriasis Area and Severity Index; MTX, methotrexate. Results are shown as mean (range).

Immunohistochemical analysis The severity of the inflammatory infiltrate in lesional epidermis and synovial tissue was comparable in both treatment groups at baseline. Forty eight hours after infusion, a significant reduction in the number of epidermal T cells was seen in patients treated with infliximab (baseline 37 (11) cells/mm, 48 hours 26 (11), p = 0.028), in contrast with patients treated with placebo (18 (8) v 43 (20), NS). This observation was mirrored by analysis of synovial tissue, showing a decrease in the total number of T cells 48 hours after treatment with infliximab (67 (56) cells/mm² v 32 (30), p = 0.043), but no significant change in the placebo group (110 (62) v 46 (21), NS). Analysis of
Figure 1 Representative images of CD3+ immunohistochemical staining and TUNEL assay in lesional psoriatic skin at baseline and 48 hours after initiation of infliximab treatment. Original magnification X400.

Table 2. Results of immunohistochemical staining and TUNEL assay of lesional skin and synovial biopsies.

<table>
<thead>
<tr>
<th></th>
<th>Infliximab 3 mg/kg</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
<td>After</td>
</tr>
<tr>
<td>CD3+ epidermis</td>
<td>37 (11)</td>
<td>26 (11)</td>
</tr>
<tr>
<td>CD3+ dermis</td>
<td>159 (64)</td>
<td>136 (54)</td>
</tr>
<tr>
<td>CD3+ synovium</td>
<td>67 (56)</td>
<td>32 (30)</td>
</tr>
<tr>
<td>CD68+ intimal lining layer</td>
<td>48 (41)</td>
<td>5 (3)</td>
</tr>
<tr>
<td>CD68+ synovial sublining</td>
<td>100 (73)</td>
<td>10 (8)</td>
</tr>
<tr>
<td>TUNEL+ epidermis</td>
<td>12 (7)</td>
<td>10 (6)</td>
</tr>
<tr>
<td>TUNEL+ synovium</td>
<td>28 (10)</td>
<td>22 (10)</td>
</tr>
</tbody>
</table>

* significant reduction from baseline, p < 0.05. Epidermal counts are given as positive cells/mm. Dermal and synovial counts are given as positive cells/mm². Results are expressed as mean (SEM).

the synovial sublining also showed a significant reduction in the number of sublining macrophages in infliximab treated patients (100 (73) v 10 (8), p = 0.043), but not in the control group (111 (41) v 67 (20), NS). The decrease in macrophages in the intimal lining layer did not reach statistical significance (infliximab 48 (41) v 5 (3), NS; placebo 81 (25) v 53 (36), NS). Figure 1 and 2 and table 2 show the changes in the inflammatory infiltrate in both treatment groups.
Figure 2  Representative images of CD3+ and CD68+ immunohistochemical staining and TUNEL assay in synovial tissue at baseline and 48 hours after initiation of infliximab treatment. Original magnification X400.

Apoptosis assays The presence of apoptotic cells was determined by TUNEL assay. Sections treated with DNase (Roche) to induce DNA fragmentation were included as positive controls.

Of interest, 48 hours after baseline, the number of apoptotic cells in both skin and synovium was unaltered in both the infliximab group (epidermis: baseline 12 (7) cells/mm, 48 hours 10 (6); synovium: baseline 28 (10) cells/mm², 48 hours 22 (10), NS) and the placebo group (epidermis: baseline 33 (13), 48 hours 45 (26); synovium: baseline 58 (20), 48 hours 43 (14), NS) (fig 2). To exclude
the possibility of a false negative result as a consequence of decreased cellularity, the analysis was repeated after correction for total cell counts. This confirmed that the number of TUNEL positive cells was not increased after treatment (data not shown).
Skin sections and synovial tissue were also analyzed for caspase-3 expression, as a marker of apoptosis. As positive controls, sections from UVB treated psoriatic skin were included, which clearly showed increased caspase-3 expression. Consistent with data obtained by TUNEL assay, the expression of caspase-3 did not significantly change after treatment in either group (data not shown).

**Discussion**

The data presented in this study show that a single infusion of a relatively low dose of infliximab (3 mg/kg) significantly decreases T cell and macrophage infiltration in synovial tissue of patients with PsA 48 hours after treatment. Similarly, we observed a reduction in T cell numbers in lesional epidermis. The reductions in the cell infiltrate could not be explained by an increase in the number of apoptotic cells at the site of inflammation.

Theoretically, the effects reported here could be influenced to some extent by the concurrent treatment with MTX. This drug may be capable of inhibiting synovial cell infiltration, in part by reducing the expression of adhesion molecules in synovial tissue (25). However, all patients had active disease at the time of inclusion despite MTX, and doses were kept stable at least 28 days before the start and during the study. Therefore, it appears unlikely that concomitant MTX treatment had a significant effect on the changes in synovial and skin biopsy samples. This notion is supported by the absence of significant changes in the patients who received placebo who also continued MTX treatment.

For analysis of synovial tissue we chose to select infiltration by T cells and macrophages because both cell types are considered crucial players in the pathogenesis of synovial inflammation in PsA. Moreover, previous work in RA patients has shown a reduction in numbers of T cells (26) and macrophages (27) 2-4 weeks after a single infusion of 10 mg/kg infliximab, suggesting that TNFα blockade might exert its effects, in part, by targeting these cells in the synovium, at least in RA. The a priori restriction of the number of immunohistological variables obviously decreases the chance of erroneously reporting statistically significant effects due to multiple comparisons.
The significant decrease in inflammatory cell infiltration in synovial tissue demonstrated in the present study is consistent with the reduction in synovial inflammation shown by gadolinium-DTPA uptake at week 10, which was previously described in patients with PsA who received infliximab treatment at 5 mg/kg at weeks 0, 2, and 6 (28). In addition, an open study in a heterogeneous group of eight patients with spondylarthropathy treated with infliximab at 5 mg/kg according to the same regimen showed a decrease in synovial macrophage infiltration 12 weeks after initiation of treatment (29). The infliximab dose used in the present study (3 mg/kg) is markedly lower than that used in previous studies evaluating the effects of infliximab in psoriasis and PsA. The results suggest that the lower dosage may also be effective. Obviously, clinically meaningful effects remain to be shown in larger, clinical studies.

In line with the changes in the synovium, we describe a decrease in T cell infiltration in paired skin biopsy samples after infliximab treatment. T cells are believed to have a central role in the pathogenesis of psoriasis, based on the presence of T cells in early psoriasis lesions (30), the beneficial effects of T cell–targeted therapies like cyclosporine A (31) and alefacept (32), and the altered relation between psoriatic keratinocytes and interferon-γ compared with normal keratinocytes (33). It is tempting to speculate that a decrease in antigen driven T cells at the site of inflammation might explain, in part, the beneficial effect of anti-TNF treatment in patients with psoriasis, similar to the effects of biologic therapies specifically targeting activated T cells in psoriasis and PsA (11, 32).

The changes in skin and synovial tissue were detected very early after initiation of treatment. Similar results were recently reported in patients with RA treated with infliximab (34). Consistent with the early immunohistological changes is the sometimes rapid onset of clinical improvement and changes in the acute phase response in patients with inflammatory disorders treated with infliximab. Clinical improvement and a reduction in C reactive protein levels may occur as early as 48 hours after initiation of therapy (20, 35, 36).

In line with recent observations in RA synovium (34), the decrease in cell infiltration could not be explained by induction of apoptosis at the site of inflammation, as shown by both TUNEL assay and caspase-3 staining. Thus, it appears that the mechanism of action of infliximab therapy might differ
between RA, PsA, and psoriasis on the one hand, and Crohn's disease \(^{(37, 38)}\) on the other. In the last condition, an increase in the number of apoptotic cells in the lamina propria of the gut has been detected after infliximab therapy. A possible explanation for the discrepancy might be the difference in disease pathogenesis and tissue-specific properties. Neutralization of the effects of TNFα appears sufficient to induce clinical improvement in RA, PsA, and psoriasis even without induction of apoptosis at the site of inflammation. It should be noted that the available data suggest that treatment with both anti-TNFα antibodies and soluble TNF receptors are equally effective in RA, PsA, and psoriasis \(^{(39, 40)}\) but not in Crohn's disease \(^{(41)}\), where induction of apoptosis by anti-TNF antibody may be key to inducing clinical improvement. The decrease in cell infiltration seen in both skin and synovial tissue might be explained by reduced cell trafficking after TNFα blockade. Studies in patients with RA have shown that infliximab treatment decreases expression of adhesion molecules \(^{(26)}\) and chemokines \(^{(27)}\), molecules that are intimately involved in cell migration. Detailed studies addressing the effects of anti-TNF treatment on cell trafficking in PsA and psoriasis are, as yet, not available. In addition, we cannot exclude the possibility that infliximab may induce apoptosis in compartments other than skin and synovium, such as the bone marrow and peripheral blood, thereby affecting migration of inflammatory cells towards the synovial compartment and the skin. This remains to be shown in future studies.

In conclusion, this study demonstrates a significant reduction in cell infiltration in both lesional epidermis and synovial tissue of patients with PsA by 48 hours after a single infusion of infliximab. The data support the view that TNFα is one of the key mediators in both psoriasis and PsA.

References


